MDACC Study No:2010-0167 ( NCT No: NCT01134120)
Title:A Phase I Study of LY2784544 in Patients with JAK2 V617F-Positive Myeloproliferative Disorders
Principal Investigator:Srdan Verstovsek
Treatment Agent:JAK2 Inhibitor; LY2784544
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of LY2784544 that can be given to patients with myeloproliferative disorders.
The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase I
Treatment Agents:JAK2 Inhibitor
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eli Lilly and Company
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults